CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience

CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience

Abstract Background Calcitonin gene-related peptide (CGRP) (receptor) antibodies (erenumab, fremanezumab and galcanezumab) are increasingly used in prophylactic treatment of migraine. In the approval studies, severely affected patients with migraine and chronic daily headache without any headache fr...

Full description

Bibliographic Details
Main Authors: Armin Scheffler, Hannah Schenk, Sebastian Wurthmann, Michael Nsaka, Christoph Kleinschnitz, Martin Glas, Dagny Holle
Format: Article
Language:English
Published: BMC 2021-09-01
Series:The Journal of Headache and Pain
Subjects:
Migraine
CGRP antibody
Therapy
Real-world
Chronic daily headache
Online Access:https://doi.org/10.1186/s10194-021-01323-6

Internet

https://doi.org/10.1186/s10194-021-01323-6

Similar Items